All hail the consumer in 2016! Consumers will shop with their feet to find quality, value, and a great experience.

Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman

Oliver Wyman's Health & Life Sciences global managing partner weighs in on consolidation, consumerism, and rising drug costs.

Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman

Healthcare is on the precipice of a transformation where the one size fits all model of yesterday is being replaced by innovative players serving the needs of distinct customer segments and purchase occasions.

Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman

A lot of health systems are talking about shifting from volume to value and the importance of population health. But many are getting stuck betwixt and between. The transformation carries major financial risk and is an organizationally complex undertaking. That’s why a recent ad in the New York Times Magazine by the Mount Sinai Health System got noticed for its simple declarative vision: “If our beds are filled, it means we’ve failed.”

Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman
Chief Population Health Officer, Mount Sinai Health System

In Idea 10 of Oliver Wyman’s “Ten Ideas” compendium, Health & Life Sciences Managing Partner Terry Stone explores how encouraging consumers to make healthier choices will yield big savings and better outcomes.

Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman

Insights in your inbox

Subscribe

Recently announced mergers are poised to disrupt the health plan landscape and tip us into a volatile period that will likely feature further consolidation.

Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman

In an Industry Analysis perspective for Managed Healthcare Executive, Oliver Wyman's Terry Stone lays out how, for health plans, the Anthem-Cigna, Aetna-Humana, and Centene-Health Net deals signal that the industry is responding to structural changes in healthcare that have been building over the past few years.

Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman

Is like-like consolidation a good thing? Is it sufficient to create real value? We make the case that this approach is too cautious over the long term.

Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman
Head of Health & Life Sciences, North America, Oliver Wyman

Since 2012, MobCon has brought together top industry influencers to showcase how mobile innovations and strategies can transform business. Today, its MobCon Digital Health conference in Minneapolis is zeroing in on how advances in technology are moving healthcare forward. Terry Stone, Oliver Wyman’s managing partner for Health & Life Sciences, will be leading a breakout session on the Patient-to-Consumer Revolution.

Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman

Last Friday the US Food and Drug Administration approved the use of the first biosimilar product in the United States. Oliver Wyman's Health & Life Sciences Managing Partner Terry Stone joins with colleague and pharma expert Jeff Hewitt to explain why this is the start of a new era for the high-priced biologics market.

Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman

Insights in your inbox

Subscribe